SEQUENOM INC (SQNM)
(Delayed Data from NSDQ)
$2.39 USD
-0.01 (-0.42%)
Updated Sep 6, 2016 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[SQNM]
Reports for Purchase
Showing records 1 - 20 ( 188 total )
Industry: Medical - Biomedical and Genetics
Model Update - Tweaking Revenue - GMs Forecasts - Remaining Cautious Post NTRA Results - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
Expecting Weak 3Q15 Results Post Preannouncement - Pricing - Share Loss in Focus - Bold Restructuring Is In Order - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
Lowering Estimates - PT Following Weak Guidance Update - Competition - Pricing At Issue - Reducing PT to $1.50
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
2Q15 Recap - Revenue Soft - Volume Growth In-line - ILMN Patent Pool Less Lucrative Than We Were Thinking - Lowering PT to $2.50 - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
2Q15 Preview - Consensus Revenue Forecasts Appear Overly Negative - Market Share - ASPs Appear Ok - Maintain NEUTRAL - Lowering PT to $3.50
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
ACOG Updates NIPT Guidelines - Slight Positive, In Our View, But Kneejerk Investor Reaction May Be Negative - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
ACOG Updates NIPT Guidelines - Slight Positive, In Our View, But Kneejerk Investor Reaction May Be Negative - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL from OUTPERFORM Following So So 1Q15 Results - Moving to Sidelines After Recent Runup - Just Ok Volume - Sales Growth
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
Wobbly 4Q Sales Offset by GM Strength - Breakeven - Market Share Story Intact - Karyotype Test - Avg. Risk Catalyst Are Reasons to Own - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events from the Week of March 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
3Q14 Test Volumes & Sales Soft Due to Competition & Seasonality - October Results Peek Provides Confidence - Opex Very Good - PT to $4.50 - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
Risk Reward Favorable Going in to 3Q Earnings - Checks Suggest Stable Reimbursement - Minor Quest, VisibiliT & Mayo Sales Built In - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
Medical Diagnostics and Life Sciences Tools - Ariosa Publishes New NIPT Approach
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Pro-Forma 2Q14 Results Solid - Volumes Good Enough - GM & Opex Improve- Announces Mayo Clinic Deal
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Expecting in-line 2Q14-Updating Model to Reflect Pro Forma 2Q14
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences - Upcoming Events for the Week of June 30
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L